La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Cencora Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Bob Mauch

Amministratore delegato

US$7.7m

Compenso totale

Percentuale dello stipendio del CEO	12.7%
Mandato del CEO	2yrs
Proprietà del CEO	0.01%
Durata media del management	4.4yrs
Durata media del Consiglio di amministrazione	9.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Bob Mauch rispetto agli utili di Cencora?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	US$2b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	n/a	n/a	US$2b
Sep 30 2023	US$8m	US$975k	US$2b
Jun 30 2023	n/a	n/a	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$2b
Sep 30 2022	US$6m	US$850k	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	n/a	n/a	US$2b
Sep 30 2021	US$6m	US$800k	US$2b
Jun 30 2021	n/a	n/a	-US$4b
Mar 31 2021	n/a	n/a	-US$4b
Dec 31 2020	n/a	n/a	-US$3b
Sep 30 2020	US$4m	US$700k	-US$3b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	n/a	n/a	US$649m
Sep 30 2019	US$4m	US$675k	US$855m
Jun 30 2019	n/a	n/a	US$956m
Mar 31 2019	n/a	n/a	US$930m
Dec 31 2018	n/a	n/a	US$1b
Sep 30 2018	US$3m	US$675k	US$2b

Compensazione vs Mercato: La retribuzione totale di Steve ($USD 17.51M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 5.47M ).

Compensazione vs guadagni: La retribuzione di Bob è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Bob Mauch (57 yo)

2yrs

Mandato

US$7,697,850

Compensazione

Dr. Robert P. Mauch, PharmD, Ph D., also known as Bob, is an Executive Vice President at Cencora, Inc. (formerly known as AmerisourceBergen Corporation) since February 2015 and served as its Group Presiden...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Steven Collis	Executive Chairman	13.4yrs	US$17.51m	0.15% € 62.3m
Robert Mauch	President	2yrs	US$7.70m	0.012% € 5.3m
James Cleary	Executive VP & CFO	5.9yrs	US$5.45m	0.058% € 24.9m
Elizabeth Campbell	Executive VP & Chief Legal Officer	3.1yrs	US$4.03m	0.0042% € 1.8m
Lazarus Krikorian	Senior VP	12.8yrs	Nessun dato	0.010% € 4.4m
Bennett Murphy	Senior Vice President of Investor Relations	no data	Nessun dato	Nessun dato
Jennifer Dubas	Senior VP & Chief Compliance Officer	no data	Nessun dato	Nessun dato
Silvana Battaglia	Executive VP & Chief Human Resources Officer	5.8yrs	US$3.48m	0.0056% € 2.4m
Ann Anaya	Senior VP and Chief Diversity Equity & Inclusion Officer	2.8yrs	Nessun dato	Nessun dato
J. Quinn	VP & Corporate Treasurer	no data	Nessun dato	Nessun dato
Brian Nightengale	President of Good Neighbor Pharmacy	8.2yrs	Nessun dato	Nessun dato
Kourosh Pirouz	VP, Associate General Counsel & Secretary	no data	Nessun dato	Nessun dato

4.4yrs

Durata media

58yo

Età media

Gestione esperta: Il team dirigenziale di ABG è considerato esperto (durata media dell'incarico 4.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Steven Collis	Executive Chairman	13.4yrs	US$17.51m	0.15% € 62.3m
Robert Mauch	President	no data	US$7.70m	0.012% € 5.3m
Lauren Tyler	Independent Director	less than a year	Nessun dato	Nessun dato
Richard Gochnauer	Independent Director	16.1yrs	US$300.10k	0.011% € 4.9m
Mark M. Durcan	Lead Independent Director	9.1yrs	US$380.05k	0.010% € 4.3m
Lon Greenberg	Independent Director	11.4yrs	US$332.60k	0.0057% € 2.5m
Kathleen Hyle	Independent Director	14.4yrs	US$320.10k	0.011% € 4.6m
Dennis Nally	Independent Director	4.8yrs	US$375.36k	0.0044% € 1.9m
Ornella Barra	Director	9.8yrs	Nessun dato	Nessun dato
Henry McGee	Independent Director	19.9yrs	US$320.10k	0.0077% € 3.3m
Lorence Kim	Independent director	2yrs	US$397.33k	0.000090% € 38.6k
Redonda Miller	Independent Director	1.8yrs	US$311.82k	0.00080% € 342.7k

9.4yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ABG sono considerati esperti (durata media dell'incarico 9.3 anni).

Cencora Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Cencora, Inc. Elects Frank Clyburn as New Independent Director, Effective October 1, 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Chairman recently sold €8.1m worth of stock

Insider recently sold €1.8m worth of stock

Recent updates

Cencora, Inc. to Report Q4, 2024 Results on Nov 06, 2024

Cencora, Inc. Elects Frank Clyburn as New Independent Director, Effective October 1, 2024

Third quarter dividend of US$0.51 announced

Third quarter 2024 earnings released: EPS: US$2.44 (vs US$2.37 in 3Q 2023)

Cencora, Inc. Declares Quarterly Cash Dividend, Payable on August 26, 2024

Cencora, Inc. to Report Q3, 2024 Results on Jul 31, 2024

Second quarter dividend of US$0.51 announced

Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on May 24, 2024

Second quarter 2024 earnings released: EPS: US$2.11 (vs US$2.15 in 2Q 2023)

Cencora, Inc. (NYSE:COR) announces an Equity Buyback for $2,000 million worth of its shares.

Cencora, Inc. to Report Q2, 2024 Results on May 01, 2024

Cencora, Inc. Reaffirms Guidance for Year 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora’s FormularyDecisions Launches Payer Resource for Cell and Gene Therapy Products

First quarter dividend of US$0.51 announced

First quarter 2024 earnings released: EPS: US$3.01 (vs US$2.35 in 1Q 2023)

Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on February 26, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc. to Report Q1, 2024 Results on Jan 31, 2024

Now 20% undervalued

Chairman recently sold €8.1m worth of stock

Insider recently sold €1.8m worth of stock

Cencora, Inc. Declares Quarterly Dividend, Payable November 27, 2023

Full year 2023 earnings released: EPS: US$8.62 (vs US$8.15 in FY 2022)

Cencora, Inc. to Report Q4, 2023 Results on Nov 02, 2023

Amerisourcebergen Corporation Elects Werner Baumann and Lauren Tyler to Its Board of Directors

Third quarter 2023 earnings released: EPS: US$2.37 (vs US$1.95 in 3Q 2022)

AmerisourceBergen Corporation Declares Quarterly Cash Dividend, Payable on August 28, 2023

AmerisourceBergen Corporation to Report Q3, 2023 Results on Aug 02, 2023

TPG Inc. (NasdaqGS:TPG), AmerisourceBergen Corporation (NYSE:ABC) and the management team of OneOncology, Inc. acquired OneOncology, LLC from General Atlantic Service Company, L.P. and others.

Executive VP & Chief Legal Officer recently sold €675k worth of stock

Second quarter 2023 earnings released: EPS: US$2.15 (vs US$2.62 in 2Q 2022)

Insider recently sold €282k worth of stock

Senior VP recently sold €832k worth of stock

First quarter 2023 earnings released: EPS: US$2.35 (vs US$2.15 in 1Q 2022)

An unknown buyer acquired Brazil specialty business from AmerisourceBergen Corporation (NYSE:ABC).

AmerisourceBergen Corporation, Annual General Meeting, Mar 09, 2023

AmerisourceBergen Corporation, Annual General Meeting, Mar 09, 2023

AmerisourceBergen Corporation to Report Q1, 2023 Results on Feb 01, 2023

Insider recently sold €129k worth of stock

Executive VP & Chief Strategy Officer recently sold €475k worth of stock

Full year 2022 earnings released: EPS: US$8.15 (vs US$7.48 in FY 2021)

AmerisourceBergen Corporation Elects Redonda Miller to Its Board of Directors, Effective January 1, 2023

AmerisourceBergen Corporation has completed a Follow-on Equity Offering in the amount of $1.546 billion.

Full year 2022 earnings released: EPS: US$8.15 (vs US$7.48 in FY 2021)

AmerisourceBergen Corporation Appoints Robert P. Mauch as Executive Vice President and Chief Operating Officer

AmerisourceBergen Corporation to Report Q4, 2022 Results on Nov 03, 2022

AmerisourceBergen Elects Lorence H. Kim, M.D., to Its Board of Directors

AmerisourceBergen Corporation (NYSE:ABC) agreed to acquire Pharmalex Holding Gmbh from AUCTUS Capital Partners AG for €1.3 billion.

AmerisourceBergen Corporation (NYSE:ABC) agreed to acquire Pharmalex Holding Gmbh for €1.28 billion.

Insufficient new directors

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media